

What COVID-19 taught us: New opportunities and pathways from telemedicine and novel antiseptics in wound healing

Alessandro Scalise¹ | Marco Falcone² | Giampiero Avruscio³ | Enrico Brocco⁴ | Eugenio Ciacco⁵ | Aurora Parodi⁶ | Rolando Tasinato⁷ | Elia Ricci⁸

¹Department of Plastic and Reconstructive Surgery, Polytechnical University, School of Medicine, Ancona, Italy

²Department of Clinical and Experimental Medicine, University of Pisa, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy

³Angiology Unit, Department of Cardiac, Thoracic and Vascular Sciences, Hospital-University of Padua, Padua, Italy

⁴Medicine-Diabetic Foot Unit, Policlinico Abano Terme, Padova, Italy

⁵Pharmacy Unit, San Salvatore Hospital, ASL 1 Abruzzo, L'Aquila, Italy

⁶DiSSal Dermatologic Clinic, University of Genoa/Dermatologic Clinic Hospital-Policlinic San Martino IRCCS, Genoa, Italy

⁷General surgery Department, A.s.l. 3 Veneto, Mirano Hospital, Venezia, Italy

⁸Difficult Wounds Service, Casa di Cura San Luca, Pecetto Torinese (TO), Italy

Correspondence

Alessandro Scalise, Department of Plastic and Reconstructive Surgery, Polytechnical University, School of Medicine, Ancona, Italy.

Email: alessandro.scalise@ospedaliriuniti.marche.it

Abstract

The COVID-19 pandemic deeply impacted the capacity of the health systems to maintain preventive and curative services, especially for the most vulnerable populations. During the pandemic, the wound healing centres in Italy assisted a significant reduction of the frequency of their hospital admission, since only urgencies, such as severe infections or wound haemorrhagic complications, were allowed to the hospital. The aim of this multidisciplinary work is to highlight the importance of a new pathway of wound care with patient-based therapeutic approach, tailored treatments based on the characteristics of the wound and fast tracks focused on the outpatient management, reserving hospital assessment only for patients with complicated or complex wounds. This analysis highlights the point that patients with chronic wounds need to be critically evaluated in order to find the best and most appropriate care pathway, which should vary according to the patient and, especially, to the characteristics of the wound. Moreover, the most adequate topic antiseptic should be started as soon as possible. An appropriate and correct management of the wound care will allow to link the knowledge based on years of clinical practice with the new challenges and the need to visit patients remotely, when possible.

KEYWORDS

antiseptics, COVID-19, fast track, telemedicine, wound healing

Key Messages

- the COVID-19 pandemic deeply impacted the health systems worldwide
- during the pandemic, the wound healing centres in Italy assisted a significant reduction of the frequency of their hospital admission
- patients with chronic wounds need to be critically evaluated in order to find the best and most appropriate care pathway

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2021 The Authors. *International Wound Journal* published by Medicalhelplines.com Inc (3M) and John Wiley & Sons Ltd.

- an appropriate and correct management of the wound care will allow to link the knowledge based on years of clinical practice with the new challenges and the need to visit patients remotely, when possible

1 | INTRODUCTION

The COVID-19 pandemic deeply impacted the capacity of the health systems to maintain preventive and curative services, especially for the most vulnerable populations. A major challenge has been reserved to the wound care management, which needed to be significantly reorganised to evolve and to allocate energies and resources in a new model of care.

During the pandemic, the wound healing centres in Italy assisted a significant reduction of the frequency of their hospital admission because only urgencies, such as severe infections or wound haemorrhagic complications, were allowed to the hospital.¹ On the other hand, home care organisations have not always been able to meet all care needs with serious harm to patients and increased health care costs.

For this reason, it is crucial to tailor the management of wound care according to patient-related risk factors and based on wound microenvironment characteristics and on the most appropriate multidisciplinary care pathways for each wound type.

According to the time of healing, wounds can be classified into acute and chronic wounds²; wound repair depends on numerous factors,³ and chronic wounds do not follow the normal steps of the wound healing process, which usually takes less than 3 months.^{4,5}

It has been known that some patient's related risk factors can contribute to the establishment of complex and chronic wounds. Among these factors, sex,⁶ gender⁷ and nutrition⁸ might play an important role. Impaired mobility represents an important variable in the development of chronic wounds, and it can represent a risk factor, especially for pressure ulcers.⁹ Concomitant diseases can impact the healing, as well as the related therapies. Firstly, some particular diseases, such as vasculitis,¹⁰ autoimmune diseases,¹⁰ immunological disorders and diabetes can exacerbate the complexity of the wound.^{11,12} Moreover, catheter- or valve-bearing patients and patients treated with particular medications (such as corticosteroids or other immunosuppressive agents or hydroxyurea) are more prone to develop complex wounds. All the variables mentioned above, together with a high microbial load, the presence of foreign bodies or other environmental factors,¹¹ can deeply delay (or make impossible) the wound healing. An appropriate clinical risk assessment is mandatory, as reported in Table 1.

The aim of this multidisciplinary work is to highlight the importance of a new pathway of wound care with patient-based therapeutic approach, tailored treatments based on the characteristics of the wound and fast tracks focused on the outpatient management, reserving hospital assessment only for patients with complicated or complex wounds.

The plastic surgeon plays a central role in the management of chronic and complex wounds, through an accurate theoretical knowledge of the tegumentary system, the wound healing process and the practical knowledge of the different available treatments and instruments of skin wounds.

In this view, it is necessary to merge the well-established clinical practice in wound care with technological innovations driven by the pandemic in both modern dressings, and telemedicine and Artificial intelligence (AI) for the multidisciplinary assessment of non-healing wounds.

1.1 | Microenvironment

The reasons for healing failure can be various, but the microenvironment plays a crucial role. The microenvironment is defined as the extracellular compartment and can be classified as dry, moist or wet, depending on the level of hydration.¹³

Between the components of the microenvironment, the presence of vascular endothelial dysfunction results in a reduced activity of the endothelial nitric oxide synthetase (eNOS) and an overproduction of the reactive oxygen species (ROS).¹⁴ The function of ROS in wound healing varies, including the recruitment of different immune cells to the wound site (which are involved in the repair process) and the regulation of angiogenesis. Also, ROS are produced by macrophages to kill pathogens. For these reasons, ROS manipulation is a promising element, which can be considered when treating the wound.¹⁵ New therapeutic strategies aimed to improve also the MMPs regulation for a better treatment of the wound healing.¹⁶ **Matrix metalloproteinases** (MMPs) are a group of calcium-dependent zinc proteins, which are involved in the degradation of the extracellular matrix. These proteins can be classified based on their substrate affinity in collagenases, gelatinases, stromelysins, matrilysins, metalloelastases, membrane-type MMPs and

TABLE 1 Clinical risk assessment

Endogenous	Exogenous
Immunosuppression	Prosthesis
Diabetes	Systemic therapies
Malnutrition	
MRSA	
Surgical wounds	

other MMPs.¹⁷ Their activity depends on different cell types, such as fibroblasts, endothelial cells and keratinocytes, in response to numerous cytokines, hormones and growth factors.¹⁸ A dysregulation in MMPs can prolong the inflammatory state and increase the timing of the healing.¹⁹

The pH of the microenvironment influences both MMPs and bacterial growth and might be considered a healing parameter and a possible target to prevent a wound from becoming a non-healing wound. The intact skin is characterised by a pH range between 4 and 6, depending on the body location and age. On the contrary, the wound microenvironment is characterised by a pH above 7, which leads to the growth of the most common bacteria.²⁰ At the moment, pH value is the only variable related to the microenvironment, which can be assessed, even at home, by the patient or his caregiver, using paper strips²¹ or a near-infrared fluorescent pH sensing film.²²

The bacterial load is another factor involved in the healing delay.²³ In fact, the colonisation of the wound by bacteria may really facilitate the establishment of the chronic wound, which is mostly characterised by the presence of *Pseudomonas* spp, *Staphylococcus* spp, *Enterobacter* and even some nosocomial pathogens, such as *Stenotrophomonas* spp.²⁴ These bacteria can be free or can create a biofilm, a complex structure consisting of bacterial cells, extracellular matrix and extra polymeric substance (EPS).²⁵ Biofilm is characterised by slow-growing bacteria, which develop multidrug tolerance, and the extracellular matrix⁵ prevents the action of orally administered antibiotic therapy, resulting in the establishment of antibiotic resistance,²⁶ often associated with the indiscriminate abuse of systemic therapy.²⁷

Factors that might be involved in the establishment of wound healing are reported in Figure 1.

The British Society for Antimicrobial Chemotherapy (BSAC) and the European Wound Management Association (EWMA) recommended the preferential use of antimicrobials not containing antibiotics for the treatment of infected wounds.²⁸ Antibiotics-free antimicrobials are administered through the cutaneous route, which may guarantee a high concentration and is characterised by a

lower risk to develop resistance.²⁹ On the other hand, this route is characterised by some limitations, such as the depth of penetration, possible side effects, the potential cellular damage and the patient compliance.²⁷

1.2 | Role of the antiseptics in the wound care

Complex wounds include different types of lesions, which can be classified, according to their aetiology, as arterial, venous, diabetic and pressure ulcers.³⁰ All these wounds are characterised by excessive levels of inflammation, persistent infections, drug-resistant bacteria and a lack in response to healing.³¹ Moreover, all of them can deeply impact patients' quality of life.^{4,32,33,34} The dressing of the complex wounds should always follow the TIME principles (tissue debridement, infection or inflammation, moisture balance and edge effect),³⁵ which include the tissue debridement, the infection control, the moisture balance and edges the wound.³⁶

A precise assessment of the infection needs to be performed. Nowadays, two groups of criteria are used to identify chronic wounds with infectious processes, called NERDS and STONEES. NERDS criteria are adopted when a biofilm or a critical colonisation is present. NERDS wounds are non-healing, exudative wounds, which bleeds, smells and debris.^{37,38} On the other hand, STONES criteria are adopted to assess the infection. STONEES wounds are characterised by increased temperature, exudative, erythema or oedema and smell.^{37,38}

A critically infected or colonised wound must be treated with systemic antibiotics in order to treat the infection, restore the microenvironment and to facilitate healing.²⁷ On the other hand, the risk of sepsis is null, wounds must be dressed with antiseptics, defined as chemical/based agents, which are able to reduce the bacterial load.³⁹ Because the aim of the wound care consists in removing the non-vital tissue, to prevent the infections, to promote the healing and to control the pain,⁴⁰ an antiseptic must be aggressive on biofilm and non-viable tissues, but also it should ideally show a similar tolerability than physiological saline solution, Ringer solution or inert hydrogels. In fact, during the wound care, the adjacent tissues result exposed to the antiseptic, highlighting the need to carefully evaluate its tolerability.⁴¹

Although antiseptics are widely used on the intact skin, to prevent critical colonisation, their use in the dressing of open wounds (such as lacerations, abrasions, burns and chronic ulcers) is still debated.⁴⁰ In fact, antiseptics showed a concentration-dependent cytotoxic activity in vitro against fibroblasts, keratinocytes and leucocytes, involved in the healing process.⁴⁰ According




FIGURE 1 Factors that can influence the microenvironment. eNOS, endothelial nitric oxide synthetase; MMP, matrix metalloproteinases; ROS, reactive oxygen species

to Italian law, antiseptics and disinfectants aimed to treat the skin and mucosal tissue are defined as pharmacological drugs and are managed according to the Italian medicine agency.⁴² On the contrary, if the mechanism of action mostly consists in a mechanical effect (as in case of solutions or gauze), the product is defined as a medical device.⁴¹

According to the CDC, the efficacy of antiseptics depends on numerous factors related to the microorganism (such as their number and location, their resistance), to the product (such as the concentration and the power) or to the environment (physical and chemical factors, organic and inorganic matter, duration of exposure).⁴³

The right antiseptic approach should be created by deeply analysing the efficacy and tolerability of the different products and the patient's conditions, in order to prevent systemic infections and to allow the treatment in an outpatient setting. Finally, the **cost-effectiveness** should be taken into account to choose the ideal antiseptic approach,⁴¹ avoiding the use of ineffective products or conversely abuse of aggressive products. The treatment-related costs based on bioburden are reported in Table 2.

The use of antiseptic treatment should be carefully evaluated according to the patient's conditions and comorbidities (immunocompromised patients, diabetic patients or patients who underwent surgery) and the complexity of the lesion, as well as the antiseptic persistence and the time of action and the tolerability. The most used disinfectants and antiseptics are reported in Table 3.

In the light of recent wound care management reorganisation (due to the COVID 19 pandemic), the need of all-inclusive and technologic materials became increasingly strong, and the use of sterile, single-dose packaging is strongly encouraged.

1.3 | How to treat complex wounds

Topical antiseptics should be the first-line treatment to remove bacteria from the wound site in order to allow a proper healing. Unfortunately, sometimes the administration of systemic antibiotics is necessary, especially when an early and adequate antiseptics is not provided.⁴⁴ The antimicrobial treatment approach should always consider patient's conditions, possible drug-drug interactions and adverse events,^{45,46} but the main objective is to restrict the use of systemic antibiotics just to cases with confirmed clinically significant infections and/or with systemic signs of infection. The abuse of antibiotics for chronic skin lesions is one of the major drivers for antimicrobial resistance.⁴⁷ The ideal topical antimicrobial agent should be characterised by a broad spectrum, long duration, low toxicity and the ability to reach the wound without any systemic implication.⁴⁰ In case of complex wounds and severe clinical picture (such as surgical wounds and nosocomial pathogens, immunodeficient patients or patients with diabetic foot), topical treatments need to be excluded or coupled with systemic antibiotics. Acute bacterial skin and skin-structure infections (ABSSSIs) are one of the most common reasons to reach out to a health care facility. In these cases, current guidelines focus the attention on the need of antibiotics with a broad spectrum for the Gram-positive bacteria, especially MRSA. FDA recently approved the use of dalbavancin, oritavancin, tedizolid and delafloxacin in the treatment of ABSSSIs.^{48,49}

Recently, the use of long-acting antibiotics became a new therapeutic approach, which allows to treat systemic infections in an outpatient setting.⁵⁰

TABLE 2 Treatment-related costs based on bioburden

Bioburden	Setting	Treatment	Costs
Contamination	Domiciliary care	The treatment aims to control the bioburden	Low
Colonisation	Domiciliary care	Local treatment	Low
Local infection	Domiciliary care/medical office	Local treatment/antibiotics	Medium
Infection	Medical office/Hospital	Antibiotics	High
Sepsis	Hospital/ICU	Antibiotics	Very High

TABLE 3 Most used disinfectants and antiseptics

Category	Active compound	Activity
Disinfectants		
Low level	quaternary ammonium	Gram positive (++), Gram negative (+), Mycobacterium spp (-), Fungi (+-), Viruses (-), Spores (-)
Intermediate level	70-90% isopropyl and ethylic alcohol	Gram positive (+++), Gram negative (+++), Mycobacterium spp (+-), Fungi (++), Viruses (envelope: ++; no envelope +-; HIV +++), Spores (-)
High level	6% hydrogen peroxide	Gram positive (++), Gram negative (+++), Mycobacterium spp (++), Fungi (+), Viruses (+), Spores (-)
	1.1-0.05% sodium hypochlorite electrolytic solution	Gram positive (+++), Gram negative (+++), Mycobacterium spp (++), Fungi (++), Viruses (++), Spores (++)
Antiseptics		
Low level	Chlorhexidine	Gram positive (+++), Gram negative (++), Mycobacterium spp (+-), Fungi (+), Viruses (envelope: +; no envelope: -), Spores (-)
Intermediate level	0.05% sodium hypochlorite electrolytic solution	Gram positive +++, Gram negative +++, Mycobacterium spp: ++, Fungi: ++, Viruses (envelope: ++; no envelope: ++), Spores: ++.
	iodophors with more than 40/50 mg of free iodine	Gram positive (+++), Gram negative (+++), Mycobacterium spp (++), Fungi (++), Viruses (++), Spores (+)
	70-90% isopropyl and ethylic alcohol	Gram positive (+++), Gram negative (+++), Mycobacterium spp (+-), Fungi (++), Viruses (envelope: ++; no envelope +-; HIV +++), Spores (-)

1.4 | Multidisciplinary approach and fast track: through a new conception of the wound care

As reported above, chronic wounds involve different patients (most of the time affected by chronic diseases) in different care facilities. These lesions require a multidisciplinary approach, able to involve different health care professionals, which can contribute to the resolution of the wound.^{51,52,53,54} The ideal multidisciplinary team should include general and vascular surgeons, a wound care nurse, an infectious disease specialist, a physical therapist, a dietitian and an internist,⁵⁵ with clearly structured interactions and well-defined care pathways and algorithms.⁵⁶

A new and innovative approach is the “fast track model”, which consists of a multimodal care pathway with the aim to promote an early recovering and reduce hospitalisation.⁵⁷

The recent COVID-19 pandemic challenged the health care system all over the world, deeply affecting numerous medical practices. In fact, numerous patients with chronic diseases assisted to a reduction of the medical care. Among all the fields, the wound care management resulted in a necessary modification of the assisted care pathways.⁵⁸ In this period, because the access to the hospital facility was strictly limited to emergency care and COVID-19 patients, a new strategy needed to be applied in order to facilitate the wound care management in high-risk patients.⁵⁹ In fact, without a regular dressing,

the chances to develop infections are high and often might increase the risk for the loss of limbs.⁶⁰ During this challenging era, facilities needed to reorganise their care pathways, in order to protect the patients and also the personnel.³² Rogers and colleagues developed a triage system in order to better classify the wounds based on their characteristics. The aim was to better manage each patient in the adequate context (hospital or outpatient setting) and to avoid hospital overcrowding, as well as treating each patient according to his conditions.⁶⁰

Investigators created four levels of priority based on the infection. The first level of priority included moderate infections and sepsis, gas gangrene and acute limb-threatening ischaemia; the second level of priority included patients with mild and moderate infections, dry gangrene, osteomyelitis, chronic limb ischaemia, worsening foot ulcers and active Charcot foot; the third level of priority included improving foot ulcers and inactive Charcot foot. Finally, the four levels included the majority of the diabetic patients with stable disease with foot wounds. According to these criteria, level one patients should be treated in the hospital setting, level two patients should be treated in an outpatient clinic, office-based laboratory, surgery centre or podiatry office, while level three and four patients can be treated at home, taking the advantages of the telemedicine.⁶⁰

1.5 | Telemedicine and artificial intelligence

Data showed in the studies highlighted the efficacy and safety of telemedicine in wound care, as well as a non-inferiority compared with standard care.⁶¹ According to Cannavale et al, the use of telemedicine during the COVID-19 pandemic in Italy aided the management of the chronic wound even in critical patients, highlighting the chance to apply this new care pathway in the day-by-day wound management.⁵⁹

The assessment of the patients through telemedicine needs to be conducted according to some outcome indicators, such as the time of healing and colorimetric evaluations.⁶²

According to Scalise and colleagues, a normal telemedicine consultation usually consists of 25 minutes visit and allows to clearly evaluate both preventive and therapeutic devices, as well as the type of dressing.¹ Telemedicine really improved access to medical consultations during the COVID-19 pandemic, as reported in Figure 2.¹

AI, based on algorithms, which can self-learn and refine overtime, could be the solution for a better

wound care practice. In fact, through the use of this technology, each clinician could share his experience with other colleagues all over the world, being part of a large volume of data collection. This could help to standardise the practice and to improve the level of specialisation. Moreover, AI could help patients and caregivers to perform the wound dressing in the outpatient setting.⁶³

Bacterial fluorescence imaging is a new method, which consent to visualise and monitor the bacterial load in the wound in real time, using a 405 nm violet light. This light is able to excite bacteria and tissue within the wound, causing the emission of a fluorescent light. The outputs consist of a green, fluorescent emission in case of non-contamination, and a red or cyan fluorescence when bacteria are present.⁶⁴ Moreover, it has been demonstrated that a red light might be predictive of a moderate/heavy bacterial load.⁶⁵ Recently, this system has been adapted and used to implement the role of telemedicine in wound care. This system includes a device, which is able to send the images of the wound to the clinician in real time, allowing to assess the wound, to measure it, to evaluate the bacterial load and to provide wound care advice via telemedicine.⁶⁶

Wound Viewer is a new AI medical device, which has been recently tested. This device is able to collect different clinical data, such as three-dimensional wound measurement, tissue composition and wound classification according to the WBP protocol. Data are collected and shared through a protected data system. In order to evaluate the precision and the usefulness of the device in the remote wound evaluation, a clinical trial has been conducted among 150 patients. The results showed that AI would really help the clinician to conduct an effective remote wound assessment, reaching 97% of accuracy in the WBP classification and tissue segmentation analysis compared with that performed by clinicians.⁶⁷

2 | CONCLUSIONS

COVID-19 pandemic has really challenged the worldwide health care system, underlying critical issues and improvement needs. Mostly chronic and critical patients suffer for this difficult situation, and a modification and a reorganisation of the standard of care was needed.

In this scenario, patients with chronic wounds need to be critically evaluated in order to find the best and most appropriate care pathway, which should vary according to the patient and, especially, to the characteristics of the wound. The most




FIGURE 2 Improvements in the access to medical consultations due to telemedicine. A, Reduction in the follow-up visits due to the COVID-19 pandemic. B, Number of outpatients and hospital consultations before and after the telemedicine. All values are expressed as percentage. Graphical elaboration from Scalise, 2020¹

adequate topic antiseptic should be started as soon as possible, in order to restore the homeostasis in the microenvironment and to avoid, in the absence of systemic infections, the indiscriminate administration of antibiotics, which could lead to dangerous mechanism of resistance.

An evaluation of the lesion should be performed in order to avoid, if possible, to visit the patient and treat the wound in a hospital setting, preferring a home care management. Patients and caregivers should be educated and trained, and telemedicine should be preferred if possible.

An appropriate and correct management of the wound care will allow to link the knowledge based on years of clinical practice with the new challenges and the need to visit patients remotely, when possible. These components will lead to the creation of a hybrid system, which will place together a traditional management with the most innovative technologies in telemedicine and AI.

ACKNOWLEDGEMENTS

The authors acknowledge Claudia Laterza, MD of Sanitanova s.r.l. and Enrica Piras for medical writing and editorial assistance. This work has been supported by an unrestricted grant by Angelini S.p.A.

CONFLICT OF INTEREST

A.S. has received grants and/or speaker honoraria from Angelini, Convatec, Smith and Nephew, Fidia, BFactory, Urigo; M.F. has received research grants and/or speaker honoraria from Angelini, Menarini, Merck Sharp & Dohme, Nordic Pharma, Pfizer, Shionogi; E.B. has received grants and/or speaker honoraria from Angelini,

Fidia Farmaceutici; A.P. is consultant for Abbvie, Almirall, Novartis, Pfizer, Leo pharma, Lilly, Galderma, Angelini, Celgene, Alfasigma.

AUTHOR CONTRIBUTIONS

Conceptualization and Supervision: Alessandro Scalise. Writing original draft preparation: Claudia Laterza, MD Sanitanova S.r.l. and Enrica Piras. Writing, review and editing: All. Literature search: Marco Falcone and Elia Ricci. Algorithm for care elaboration: Enrico Brocco, Giampiero Avruscio and Rolando Tasinato. Oversight implementation and validation: Alessandro Scalise. All authors have read and agreed to the published version of the manuscript.

DATA AVAILABILITY STATEMENT

Data sharing not applicable to this article as no datasets were generated or analysed during the current study

REFERENCES

- Scalise A, Torresetti M, Di Benedetto G. Wound healing center: analysis of preventive measures and new indications in a teaching hospital in central Italy during the Covid-19 emergency. *Int Wound J*. 2020;17(5):1538-1540. <https://doi.org/10.1111/iwj.13430>
- Velnar T, Bailey T, Smrkolj V. The wound healing process: an overview of the cellular and molecular mechanisms. *J Int Med Res*. 2009;37(5):1528-1542. <https://doi.org/10.1177/147323000903700531>
- Scalise A, Bianchi A, Tartaglione C, et al. Microenvironment and microbiology of skin wounds: the role of bacterial biofilms and related factors. *Semin Vasc Surg*. 2015;28(3-4):151-159. <https://doi.org/10.1053/j.semvascsurg.2016.01.003>

4. Bowers S, Franco E. Chronic wounds: evaluation and management. *Am Fam Phys*. 2020;101(3):159-166.
5. Drago F, Gariazzo L, Cioni M, Trave I, Parodi A. The microbiome and its relevance in complex wounds. *Eur J Dermatol*. 2019;29(1):6-13. <https://doi.org/10.1684/ejd.2018.3486>
6. Vowden P. Hard-to-heal wounds made easy. *Wounds Int*. 2011; 2(4). Available from <https://www.woundsinternational.com>
7. Ashcroft GS. Sex differences in wound healing. *Principles of Sex-Based Differences in Physiology*; Advances in Molecular and Cell Biology Amsterdam, Netherlands: Elsevier; 2004:321-328. [https://doi.org/10.1016/s1569-2558\(03\)34022-6](https://doi.org/10.1016/s1569-2558(03)34022-6)
8. Quain AM, Khardori NM. Nutrition in wound care management: a comprehensive overview. *Wounds*. 2015;27(12):327-335.
9. Moda Vitoriano Budri A, Moore Z, Patton D, et al. Impaired mobility and pressure ulcer development in older adults: excess movement and too little movement – two sides of the one coin? *J Clin Nurs*. 2020;29(15-16):2927-2944. <https://doi.org/10.1111/jocn.15316>
10. Shanmugam VK, Angra D, Rahimi H, McNish S. Vasculitic and autoimmune wounds. *J Vasc Surg Venous Lymphat Disord*. 2017;5(2):280-292. <https://doi.org/10.1016/j.jvsv.2016.09.006>
11. Dissemmond J, Assadian O, Gerber V, et al. Classification of wounds at risk and their antimicrobial treatment with polihexanide: a practice-oriented expert recommendation. *Skin Pharmacol Physiol*. 2011;24(5):245-255. <https://doi.org/10.1159/000327210>
12. Falcone M, De Angelis B, Pea F, et al. Challenges in the management of chronic wound infections. *J Glob Antimicrob Resist*. 2021;26:140-147.
13. Junker JP, Kamel RA, Caterson EJ, Eriksson E. Clinical impact upon wound healing and inflammation in moist, wet, and dry environments. *Adv Wound Care (New Rochelle)*. 2013;2(7):348-356. <https://doi.org/10.1089/wound.2012.0412>
14. Cano Sanchez M, Lancel S, Boulanger E, Nevriere R. Targeting oxidative stress and mitochondrial dysfunction in the treatment of impaired wound healing: a systematic review. *Antioxidants (Basel)*. 2018;7(8):98. Published 2018 Jul 24. <https://doi.org/10.3390/antiox7080098>
15. Dunnill C, Patton T, Brennan J, et al. Reactive oxygen species (ROS) and wound healing: the functional role of ROS and emerging ROS-modulating technologies for augmentation of the healing process. *Int Wound J*. 2017;14(1):89-96. <https://doi.org/10.1111/iwj.12557>
16. Krejner A, Litwiniuk M, Grzela T. Matrix metalloproteinases in the wound microenvironment: therapeutic perspectives. *Chronic Wound Care Manag Res*. 2016;3:29-39. <https://doi.org/10.2147/CWC.MR.S73819>
17. Caley MP, Martins VL, O'Toole EA. Metalloproteinases and wound healing. *Adv Wound Care (New Rochelle)*. 2015;4(4): 225-234. <https://doi.org/10.1089/wound.2014.0581>
18. Sabino F, auf dem Keller U. Matrix metalloproteinases in impaired wound healing. *Metalloproteinases Med*. 2015;2:1-8. <https://doi.org/10.2147/MNM.S68420>
19. Nguyen TT, Mobashery S, Chang M. Roles of matrix metalloproteinases in cutaneous wound healing. *Wound Healing—New Insights into Ancient Challenges*. London, England: Intech; 2016. <https://doi.org/10.5772/64611>
20. Schneider LA, Korber A, Grabbe S, Dissemmond J. Influence of pH on wound-healing: a new perspective for wound-therapy? *Arch Dermatol Res*. 2007;298(9):413-420. <https://doi.org/10.1007/s00403-006-0713-x>
21. Shukla VK, Shukla D, Tiwary SK, Agrawal S, Rastogi A. Evaluation of pH measurement as a method of wound assessment. *J Wound Care*. 2007;16(7):291-294. <https://doi.org/10.12968/jowc.2007.16.7.27062>
22. Li S, Vu H, Senkowsky J, Hu W, Tang L. A near infrared fluorescent pH sensing film for wound milieu pH monitoring. *Exp Dermatol*. 2019;29(1):107-111. <https://doi.org/10.1111/exd.14046>
23. Zeng Q, Macri LK, Prasad A, et al. In: Ducheyne P, ed. *Skin Tissue Engineering in Comprehensive Biomaterials*. Oxford, UK: Elsevier; 2011, 2017:467-499.
24. Rahim K, Saleha S, Zhu X, et al. Bacterial contribution in chronicity of wounds. *Microb Ecol*. 2017;73(3):710-721.
25. Rajpaul K. Biofilm in wound care. *Br J Community Nurs*. 2015; 20(Sup3):S6-S11. <https://doi.org/10.12968/bjcn.2015.20.sup3.s6>
26. Dowd SE, Sun Y, Secor PR, et al. Survey of bacterial diversity in chronic wounds using pyrosequencing, DGGE, and full ribosome shotgun sequencing. *BMC Microbiol*. 2008;8:43. <https://doi.org/10.1186/1471-2180-8-43>
27. Scalise A. The new formulation of the 0.05% sodium hypochlorite electrolytic solution for cutaneous use: reasons and advantages. *AO [Internet]*. 2021;8(1):14-22.
28. Lipsky BA, Dryden M, Gottrup F, Nathwani D, Seaton RA, Stryja J. Antimicrobial stewardship in wound care: a position paper from the British Society for Antimicrobial Chemotherapy and European Wound Management Association. *Journal of Antimicrobial Chemotherapy*. 2016;71(11):3026-3035. <https://doi.org/10.1093/jac/dkw287>
29. Punjataewakupt A, Napavichayanun S, Aramwit P. The downside of antimicrobial agents for wound healing. *Eur J Clin Microbiol Infect Dis* 2019 Jan;38(1):39–54. doi: <https://doi.org/10.1007/s10096-018-3393-5>. Epub 2018 Oct 5. PMID: 30291466.
30. Werdin F, Tennenhaus M, Schaller HE, et al. Evidence-based management strategies for treatment of chronic wounds. *Eplasty*. 2009;9:e19.
31. Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. *Adv Wound Care (New Rochelle)*. 2015;4(9):560-582.
32. Avruscio G, Adamo A, Tonello C, et al. Wound Care During the COVID-19 Emergency in Padua Hospital, Italy. *Disaster Med Public Health Prep*. 2020;1-4. <https://doi.org/10.1017/dmp.2020.448>
33. Packer CF, Ali SA, Manna B. Diabetic ulcer. [Updated 2021 Feb 20]. *StatPearls [Internet]*. Treasure Island, FL: StatPearls Publishing; 2021 <https://www.ncbi.nlm.nih.gov/books/NBK499887/>
34. Edsberg LE, Black JM, Goldberg M, McNichol L, Moore L, Sieggreen M. Revised National Pressure Ulcer Advisory Panel pressure injury staging system: revised pressure injury staging system. *J Wound Ostomy Continence Nurs*. 2016;43:585-597.
35. Halim AS, Khoo TL, Saad AZ. Wound bed preparation from a clinical perspective. *Indian J Plast Surg*. 2012;45(2):193-202. <https://doi.org/10.4103/0970-0358.101277>
36. Leaper DJ, Schultz G, Carville K, et al. Extending the TIME concept: what have we learned in the past 10 years? *Int Wound J*. 2012;9(suppl 2):1-19.

37. Woo KY, Sibbald RG. A cross-sectional validation study of using NERDS and STONEES to assess bacterial burden. *Ostomy Wound Manage*. 2009;55(8):40-48.
38. Serena TE, Harrell K, Serena L, Yaakov RA. Real-time bacterial fluorescence imaging accurately identifies wounds with moderate-to-heavy bacterial burden. *J Wound Care*. 2019;28(6):346-357. <https://doi.org/10.12968/jowc.2019.28.6.346>
39. Bednarek RS, Nassereddin A, Ramsey ML. Skin antiseptics. [Updated 2021 Feb 15]. *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2021 <https://www.ncbi.nlm.nih.gov/books/NBK507853/>
40. Slaviero L, Avruscio G, Vindigni V, Tocco-Tussardi I. Antiseptics for burns: a review of the evidence. *Ann Burns Fire Disasters*. 2018;31(3):198-203.
41. Kramer A, Dissemond J, Kim S, et al. Consensus on wound antisepsis: Update 2018. *Skin Pharmacol Physiol*. 2018;31(1):28-58. <https://doi.org/10.1159/000481545>
42. GU Serie Generale n.142 del 21-06-2006—Suppl. Ordinario n. 153
43. Center for Disease Control, 2008
44. Roth B, Neuenschwander R, Brill F, et al. Effect of antiseptic irrigation on infection rates of traumatic soft tissue wounds: a longitudinal cohort study. *J Wound Care*. 2017;26(3):79-87. <https://doi.org/10.12968/jowc.2017.26.3.79>
45. Falcone M, Meier JJ, Marini MG, et al. Diabetes and acute bacterial skin and skin structure infections [published online ahead of print, 2021 Mar 5]. *Diabetes Res Clin Pract*. 2021;174:108732. <https://doi.org/10.1016/j.diabres.2021.108732>
46. Falcone M, Paul M, Tiseo G, et al. Considerations for the optimal management of antibiotic therapy in elderly patients. *J Glob Antimicrob Resist*. 2020;22:325-333.
47. Falcone M, Paul M, Yahav D, et al. Antimicrobial consumption and impact of antimicrobial stewardship programmes in long-term care facilities. *Clin Microbiol Infect*. 2019;25:562-569.
48. Golan Y. Current treatment options for acute skin and skin-structure infections. *Clin Infect Dis*. 2019;68(Suppl 3):S206-S212. <https://doi.org/10.1093/cid/ciz004>
49. Tiseo G, Arena F, Borrè S, et al. Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. *Expert Rev Anti Infect Ther*. 2021;1-11. <https://doi.org/10.1080/14787210.2021.1926986>.
50. Falcone M, Concia E, Giusti M, et al. Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. *Intern Emerg Med*. 2016;11(5):637-648.
51. Gohel MS, Heatley F, Liu X, et al. A randomized trial of early endovenous ablation in venous ulceration. *N Engl J Med*. 2018;378(22):2105-2114. <https://doi.org/10.1056/NEJMoa1801214>
52. Hinchliffe RJ, Brownrigg JR, Andros G, et al. Effectiveness of revascularization of the ulcerated foot in patients with diabetes and peripheral artery disease: a systematic review. *Diabetes Metab Res Rev*. 2016;32(Suppl 1):136-144. <https://doi.org/10.1002/dmrr.2705>
53. Tollow P, Ogden J, Whiteley MS. The comparative impact of conservative treatment versus superficial venous surgery, for the treatment of venous leg ulcers: a systematic review of the impact on patients' quality of life. *Phlebology*. 2016;31(2):82-93. <https://doi.org/10.1177/0268355515581278>
54. Prompers L, Schaper N, Apelqvist J, et al. Prediction of outcome in individuals with diabetic foot ulcers: focus on the differences between individuals with and without peripheral arterial disease. The EURODIALE Study. *Diabetologia*. 2008;51(5):747-755. <https://doi.org/10.1007/s00125-008-0940-0>
55. Manna B, Nahirniak P, Morrison CA. Wound debridement. [Updated 2021 Feb 20]. *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; 2021 <https://www.ncbi.nlm.nih.gov/books/NBK507882/>
56. Musuuzza J, Sutherland BL, Kurter S, Balasubramanian P, Bartels CM, Brennan MB. A systematic review of multidisciplinary teams to reduce major amputations for patients with diabetic foot ulcers. *J Vasc Surg*. 2020;71(4):1433-1446.e3. <https://doi.org/10.1016/j.jvs.2019.08.244>
57. Iyer SP, Kareem Z. Fast-track protocol versus conventional protocol on patient outcome: a randomized clinical trial. *Niger J Surg*. 2019;25(1):36-41. https://doi.org/10.4103/njs.NJS_34_17
58. Tinelli G, Sica S, Guarnera G, Pitocco D, Tshomba Y. Wound care during COVID-19 pandemic. *Ann Vasc Surg*. 2020;68:93-94. <https://doi.org/10.1016/j.avsg.2020.06.044>
59. Cannavale T, Nocco G, Cozzani E, Pierantoni D, Parodi A. Managing telemedicine for wounds in the COVID-19 era: a new proposal. *Adv Skin Wound Care*. 2021;34(3):120. <https://doi.org/10.1097/01.ASW.0000733208.81005.dd>
60. Rogers LC, Lavery LA, Joseph WS, Armstrong DG. All Feet On Deck-The Role of Podiatry During the COVID-19 Pandemic: Preventing hospitalizations in an overburdened healthcare system, reducing amputation and death in people with diabetes. *J Am Podiatr Med Assoc*. 2020. <https://doi.org/10.7547/20-051>
61. Chen L, Cheng L, Gao W, Chen D, Wang C, Ran X. Telemedicine in chronic wound management: systematic review and Meta-analysis. *JMIR Mhealth Uhealth*. 2020;8(6):e15574. Published 2020 Jun 25. <https://doi.org/10.2196/15574>
62. Schultz G, Mazingo D, Romanelli M, Claxton K. Wound healing and TIME; new concepts and scientific applications. *Wound Repair Regen*. 2005;13(4 Suppl):S1-S11. <https://doi.org/10.1111/j.1067-1927.2005.1304S1.x>
63. Queen D. Artificial intelligence and machine learning in wound care-the wounded machine! *Int Wound J*. 2019;16(2):311. <https://doi.org/10.1111/iwj.13108>
64. Raizman R. Fluorescence imaging guided dressing change frequency during negative pressure wound therapy: a case series. *J Wound Care*. 2019;28(Sup9):S28-S37. <https://doi.org/10.12968/jowc.2019.28.Sup9.S28>
65. Rennie MY, Lindvere-Teene L, Tapang K, Linden R. Point-of-care fluorescence imaging predicts the presence of pathogenic bacteria in wounds: a clinical study. *J Wound Care*. 2017;26(8):452-460. <https://doi.org/10.12968/jowc.2017.26.8.452>
66. Moleculight, <https://moleculight.com/ix-telemedicine-solution/>
67. Zoppo G, Marrone F, Pittarello M, et al. AI technology for remote clinical assessment and monitoring. *J Wound Care*. 2020;29(12):692-706. <https://doi.org/10.12968/jowc.2020.29.12.692>

How to cite this article: Scalise A, Falcone M, Avruscio G, et al. What COVID-19 taught us: New opportunities and pathways from telemedicine and novel antiseptics in wound healing. *Int Wound J*. 2022;19(5):987-995. doi:10.1111/iwj.13695